IgA Nephropathy (IgAN)
30
13
15
2
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 39/100
3.3%
1 terminated out of 30 trials
66.7%
-19.8% vs benchmark
13%
4 trials in Phase 3/4
50%
1 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (30)
Clinical Experience With Sparsentan in Switzerland in IgA Nephropathy
SLN12140 in Adult Participants With IgA Nephropathy in China
A Clinical Study Evaluating the Safety and Efficacy of GT719 Universal Cell Injection in the Treatment of Immune-mediated Kidney Diseases
Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease
Efficacy and Safety of CD19 CAR-γδ T Cells in the Treatment of Relapsed/Refractory Autoimmune Nephropathy
Monthly Dosing of Atacicept in IgAN
Allogeneic CD19/BCMA CAR-T for B Cell-Related Autoimmune Disease
A Study of RG002C0106 Injection in Adult Participants With Normal Renal Function and Mild-to-Moderate Renal Impairment
Phase Ⅲ Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgAN
CAR T-cell Therapy Targeting CD19 and BCMA in Patients With B Cell Mediated Autoimmune Disease
The Randomized Controlled Study of Shenqi Yishen Granules in the Treatment of IgA Nephropathy
A Multi-center Open Label Prospective Study on Early Initiation of Targeted-release Formulation of Budesonide in Patients With Primary IgA Nephropathy
A Phase IIa Clinical Study of RG002C0106 Injection in Subjects With Primary IgA Nephropathy
Avacopan in Crescentic Immunoglobulin A Nephropathy (IgAN)
To Evaluate the Effect and Safety of Telitacicept and Standard Treatment for 6months in IgA Nephropathy
RESistance of IgA Nephropathy to Conventional and Newly-approved Therapies: an Observational, Real-life Study (RESIGAN)
Clinical Study on the Efficacy and Safety of Telitacicept in the Treatment of Pediatric IgA Nephropathy or IgA Vasculitis Nephritis
Finerenone in Patients With IgA-nephropathy: Prospective Interventional Trial
An Exploratory Clinical Study of Anti-CD19/BCMA Chimeric Antigen Receptor NK Cell Injection in the Treatment of IgA Nephropathy
Autoimmune Protocol Diet Intervention on Proteinuria in IgA Nephropathy Patients